DuBiotech is located and operates within the jurisdiction of Dubai Technology & Media Free Zone (the “Free Zone”).  The Free Zone was established in 2000 by a decree and has a distinct legal status in the UAE.

The Free Zone is regulated by an independent government body, Dubai Technology & Media Free Zone Authority (DTMFZA).   DTMFZA develops and implements transparent regulations, in accordance with international standards, which ensure that the companies operating in The Free Zone are able to compete effectively, globally.

The laws and regulations that apply to companies operating in The Free Zone are described clearly in DTMFZAs website

Industry Specific Regulatory Environment

In line with the fast development of healthcare infrastructure and its growing purchasing power, UAE has a conducive and continuously improving regulatory environment for the pharmaceutical industry. 

Today, Dubai is widely regarded as the ideal base for the Middle East operations of pharmaceutical companies. In BMI’s Pharmaceuticals & Healthcare Q4 10 Business Environment Ratings (BERs) for the MENA region, UAE retained its pole position with a score of 72.6 out of 100 - much higher than the regional average of  45.4.  Globally, the UAE is ranked 13th and is therefore comparable to some of the developed European markets. With some relatively small domestic players, the UAE pharmaceutical industry is regarded as one of the most conducive regulatory and IP regimes for foreign drug companies in the region.

In addition, the UAE Government continues to focus on improving its legislative regime to increase its competitiveness.  An array of UAE laws in their final drafts, which according to HE Sultan Bin Saeed Al Mansouri, the UAE Minister of Economy, “the improved legislation will further address concerns regarding commercial regulations and arbitration, as well as promoting efficiency, transparency, and investor confidence in the business sector”.